Oxytocin Effect in Adult Patients with Autism: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

IF 2.7 4区医学 Q3 NEUROSCIENCES

CNS & neurological disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871527321666220517112612

Zahra Kiani, Tahereh Farkhondeh, Hamed Aramjoo, Michael Aschner, Hossein Beydokhti, Aliakbar Esmaeili, Morteza Arab-Zozani, Saeed Samarghandian

{"title":"Oxytocin Effect in Adult Patients with Autism: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Zahra Kiani, Tahereh Farkhondeh, Hamed Aramjoo, Michael Aschner, Hossein Beydokhti, Aliakbar Esmaeili, Morteza Arab-Zozani, Saeed Samarghandian","doi":"10.2174/1871527321666220517112612","DOIUrl":null,"url":null,"abstract":"Introduction: The efficacy of oxytocin in the treatment of autism spectrum disorder (ASD) has not been fully characterized. This systematic review and meta-analysis study evaluated randomized controlled trials (RCTs) on the treatment of intranasally administered oxytocin for autism.Methods: The study was conducted in accordance with the PRISMA statement. Two authors searched Scopus, PubMed/ Medline, Google Scholar, and Web of Science search engines and databases from inception through December 2020. Quality assessment was carried out by with the \"ROB-2, Cochrane collaboration's tool\". The random-effects model was used for pooled analyses. I2 and Q tests were used to investigate study heterogeneity. The visual inspection of funnel plots along with Egger's regression asymmetry test was used to assess the potential sources of publication bias.Results: Ten RCTs were selected for the systematic review. No study corroborated the efficacy of oxytocin for the treatment of anxiety and repetitive behavior. One out of 4 studies reported clinical improvement in severity, and 1 out of 6 studies indicated improvement in social function. Our metaanalyses findings suggest that oxytocin shows no significant efficacy in the treatment of anxiety (SMD: -0.168, SE= 0.112; 95% CI: -0.387, 0.050, p = 0.132), repetitive behavior (SMD: -0.078, SE= 0.155; 95% CI: -0.382, 0.225, p = 0.614), social function (SMD: -0.018, SE= 0.133; 95% CI: -0.279, 0.242, p = 0.891) and severity (SMD: -0.084, SE= 132; 95% CI: -0.343, 0.175, p = 0.524) of autism. No significant heterogeneity nor publication bias were observed between studies.Conclusion: Our findings failed to corroborate the efficacy of oxytocin in the treatment of ASD. Nonetheless, given the several limitations of our study, the results should be interpreted cautiously and stimulate future research on this timely topic.","PeriodicalId":10456,"journal":{"name":"CNS & neurological disorders drug targets","volume":"22 6","pages":"906-915"},"PeriodicalIF":2.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871527321666220517112612","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 4

Abstract

Introduction: The efficacy of oxytocin in the treatment of autism spectrum disorder (ASD) has not been fully characterized. This systematic review and meta-analysis study evaluated randomized controlled trials (RCTs) on the treatment of intranasally administered oxytocin for autism.

Methods: The study was conducted in accordance with the PRISMA statement. Two authors searched Scopus, PubMed/ Medline, Google Scholar, and Web of Science search engines and databases from inception through December 2020. Quality assessment was carried out by with the "ROB-2, Cochrane collaboration's tool". The random-effects model was used for pooled analyses. I2 and Q tests were used to investigate study heterogeneity. The visual inspection of funnel plots along with Egger's regression asymmetry test was used to assess the potential sources of publication bias.

Results: Ten RCTs were selected for the systematic review. No study corroborated the efficacy of oxytocin for the treatment of anxiety and repetitive behavior. One out of 4 studies reported clinical improvement in severity, and 1 out of 6 studies indicated improvement in social function. Our metaanalyses findings suggest that oxytocin shows no significant efficacy in the treatment of anxiety (SMD: -0.168, SE= 0.112; 95% CI: -0.387, 0.050, p = 0.132), repetitive behavior (SMD: -0.078, SE= 0.155; 95% CI: -0.382, 0.225, p = 0.614), social function (SMD: -0.018, SE= 0.133; 95% CI: -0.279, 0.242, p = 0.891) and severity (SMD: -0.084, SE= 132; 95% CI: -0.343, 0.175, p = 0.524) of autism. No significant heterogeneity nor publication bias were observed between studies.

Conclusion: Our findings failed to corroborate the efficacy of oxytocin in the treatment of ASD. Nonetheless, given the several limitations of our study, the results should be interpreted cautiously and stimulate future research on this timely topic.

查看原文本刊更多论文

成年自闭症患者的催产素效应:随机对照试验的最新系统评价和meta分析。

前言:催产素在治疗自闭症谱系障碍(ASD)中的疗效尚未完全确定。本系统综述和荟萃分析研究评估了鼻内给药催产素治疗自闭症的随机对照试验(rct)。方法:按照PRISMA声明进行研究。从成立到2020年12月，两位作者检索了Scopus、PubMed/ Medline、Google Scholar和Web of Science搜索引擎和数据库。采用“rob2, Cochrane协作工具”进行质量评估。采用随机效应模型进行合并分析。I2和Q检验用于研究异质性。采用漏斗图的目视检验和Egger's回归不对称检验来评估潜在的发表偏倚来源。结果:选择10个随机对照试验进行系统评价。没有研究证实催产素对治疗焦虑和重复行为的有效性。四分之一的研究报告了严重程度的临床改善，六分之一的研究表明社交功能有所改善。我们的荟萃分析结果显示，催产素在治疗焦虑方面无显著疗效(SMD: -0.168, SE= 0.112;95% CI: -0.387, 0.050, p = 0.132)，重复性行为(SMD: -0.078, SE= 0.155;95% CI: -0.382, 0.225, p = 0.614)，社会功能(SMD: -0.018, SE= 0.133;95% CI: -0.279, 0.242, p = 0.891)和严重程度(SMD: -0.084, SE= 132;95% CI: -0.343, 0.175, p = 0.524)。研究间未观察到显著的异质性和发表偏倚。结论:我们的研究结果未能证实催产素治疗ASD的有效性。尽管如此，考虑到我们研究的一些局限性，结果应该谨慎解读，并刺激未来对这一及时主题的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS & neurological disorders drug targets 医学-神经科学

CiteScore

5.10

自引率

3.30%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Aims & Scope CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.